We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

92 hedge funds and large institutions have $167M invested in Corvus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 10

45% more capital invested

Capital invested by funds: $115M → $167M (+$51.7M)

14% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 29

8.03% more ownership

Funds ownership: 53.26% → 61.29% (+8%)

5% more funds holding

Funds holding: 88 → 92 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

30% less call options, than puts

Call options by funds: $702K | Put options by funds: $1.01M

Holders
92
Holders Change
+4
Holders Change %
+4.55%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
33
Increased
32
Reduced
10
Closed
29
Calls
$702K
Puts
$1.01M
Net Calls
-$308K
Net Calls Change
-$3.1M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$15.5M
2
BlackRock
BlackRock
New York
+$11.6M
3
PA
Perceptive Advisors
New York
+$5.23M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.86M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.81M

Top Sellers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
-$12.9M
2
Millennium Management
Millennium Management
New York
-$5.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.21M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.47M
5
Jane Street
Jane Street
New York
-$901K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$554K +$136K +37,430 +37%
Bank of America
27
Bank of America
North Carolina
$531K +$124K +34,180 +35%
Raymond James Financial
28
Raymond James Financial
Florida
$498K +$59.6K +16,379 +15%
BCM
29
BML Capital Management
Indiana
$475K +$432K +118,766 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$460K +$418K +114,954 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$443K +$403K +110,688 New
Wellington Management Group
32
Wellington Management Group
Massachusetts
$409K -$9.19K -2,525 -2%
UBS Group
33
UBS Group
Switzerland
$359K +$194K +53,320 +147%
HSBC Holdings
34
HSBC Holdings
United Kingdom
$332K +$307K +84,273 New
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$304K +$273K +75,159 +9,502%
N
36
Nuveen
North Carolina
$272K +$248K +68,064 New
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$271K -$3.21M -883,527 -93%
Osaic Holdings
38
Osaic Holdings
Arizona
$269K -$2.43K -667 -1%
BCM
39
Bridgeway Capital Management
Texas
$267K +$92.4K +25,400 +62%
JSC
40
Jackson Square Capital
California
$255K – – –
HP
41
Hikari Power
Japan
$200K – – –
MTWM
42
Masso Torrence Wealth Management
New Jersey
$200K +$54.6K +15,000 +43%
Deutsche Bank
43
Deutsche Bank
Germany
$176K +$160K +43,988 New
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$176K -$1.47M -405,111 -90%
AA
45
Ancora Advisors
Ohio
$172K +$19.1K +5,238 +14%
Invesco
46
Invesco
Georgia
$162K +$148K +40,607 New
AIM
47
Avity Investment Management
Connecticut
$131K – – –
MIM
48
MetLife Investment Management
New Jersey
$128K +$117K +32,091 New
JP Morgan Chase
49
JP Morgan Chase
New York
$122K +$93.4K +25,681 +542%
AA
50
Argent Advisors
Louisiana
$120K +$109K +30,000 New
1
2
3 4 5

CRVS Hedge Fund Activity: Q2 2025 in Review

92 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2025, worth a combined $167M — up 45% from $115M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new CRVS positions and 29 closed out — a net gain of 4 holders — while 32 added to existing stakes and 10 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $15.5M. The largest seller was Samlyn Capital, exiting entirely with an estimated $12.9M sold.

  • 92 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2025, up from 88 in Q1 2025.
  • Funds reported $167M of Corvus Pharmaceuticals stock for Q2 2025, up 45% quarter-over-quarter.
  • 33 funds opened new Corvus Pharmaceuticals positions in Q2 2025 and 29 closed out, a net change of +4 holders.
  • The largest Corvus Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $15.5M added.
  • The largest Corvus Pharmaceuticals seller in Q2 2025 was Samlyn Capital, an estimated $12.9M sold.

Based on aggregated 13F filings for Q2 2025.